Table 1.
Evaluation of Inflammation as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
| Target Population | Inhibitor | Drug Target | Phase | Combinatorial Therapy | Sample | Outcome |
|---|---|---|---|---|---|---|
| HNSCC | Bintrafusp alfa | TGF-β/PD-L1 | I | – | 32 | Median follow-up:86.4 weeks ORR: 13% DCR: 34%. |
| R/M HNSCC | Dalantercept | TGF-β | II | – | 40 | Overall response rate:5% SD:35% median PFS: 1.4 months median OS: 7.1 months |
| HNSCC | Bevacizumab | VEGF | II | Cetuximab | 46 | ORR: 16% DCR: 73% median PFS: 2.8 months median OS: 7.5 months |
| R/M HNSCC | Temsirolimus | mTORC1 | II | Carboplatin, paclitaxel | 36 | ORR: 41.7% SD: 52.3% median PFS: 5.9 months OS: 12.8 months |
| HNSCC | Tadalafil | MDSC/Treg | – | – | 35 | Reduced MDSCs in the blood and in the tumor (P < 0.05), The concentration of blood CD8 T cells was increased (p < 0.05) |
Abbreviations: HNSCC, head and neck squamous cell carcinoma; R/M HNSCC, recurrent or metastatic head and neck squamous cell carcinoma; ORR, objective response rate; SD, stable disease; DCR, disease control rate; OS, overall survival; PFS, progression-free survival.